MIPI Calculator (Mantle Cell Lymphoma)
The Mantle Cell Lymphoma International Prognostic Index (MIPI) stratifies patients with advanced-stage mantle cell lymphoma into low, intermediate, and high risk groups using four routinely measured variables: age, ECOG performance status, serum LDH relative to the upper limit of normal, and leukocyte count. When Ki-67 is available, the calculator also computes the biological MIPI (MIPIb), which refines risk stratification using the tumor proliferation index. Both the continuous score and the simplified point-based score (sMIPI) are shown.
Formula
Worked example
A 65-year-old patient with ECOG 1, LDH 300 U/L, ULN 250 U/L, WBC 8.0 x10^9/L: age term = 0.03535 x 65 = 2.298; ECOG term = 0 (ECOG 0-1); LDH ratio = 300/250 = 1.20, LDH term = 1.367 x log10(1.20) = 0.096; WBC term = 0.9393 x log10(8.0) = 0.849; MIPI = 2.298 + 0 + 0.096 + 0.849 = 3.24. Score <5.70, Low risk.
What is the MIPI?
The Mantle Cell Lymphoma International Prognostic Index (MIPI) is a validated clinical tool developed by Hoster and colleagues (Blood, 2008) to predict outcomes in patients with advanced-stage mantle cell lymphoma (MCL). Mantle cell lymphoma is a B-cell non-Hodgkin lymphoma that accounts for about 3-10% of all lymphomas and typically presents at an advanced stage with involvement of lymph nodes, bone marrow, blood, and gastrointestinal tract. Before the MIPI, clinicians used the International Prognostic Index (IPI), which was designed for diffuse large B-cell lymphoma and performs poorly in MCL. The MIPI uses four variables that are routinely collected at diagnosis and requires no additional testing beyond standard blood work, making it practical for everyday clinical use. It stratifies patients into three groups with meaningfully different survival outcomes, guiding decisions about treatment intensity.
How the MIPI Score Is Calculated
The continuous MIPI formula is: MIPI = (0.03535 x age) + 0.6978 x (1 if ECOG 2-4, else 0) + 1.367 x log10(LDH / ULN) + 0.9393 x log10(WBC). Age is entered in years. ECOG performance status ranges from 0 (fully active) to 4 (completely disabled); values of 2 or greater add 0.6978 to the score. Serum LDH is divided by the upper limit of normal (ULN) for the specific laboratory assay and reported as a ratio before the log transformation. WBC is entered in units of 10^9 cells per litre. Risk groups are defined by the resulting score: below 5.70 is low risk, 5.70 to less than 6.20 is intermediate risk, and 6.20 or higher is high risk. A simplified point-based version (sMIPI) is also available; it awards 0-3 points per variable and sums to an 11-point scale with the same three risk categories.
The Biological MIPI (MIPIb) and Ki-67
Ki-67 is a nuclear protein whose immunohistochemical staining percentage reflects how rapidly tumor cells are dividing, a key predictor of aggressiveness in lymphomas. Adding Ki-67 to the standard MIPI produces the biological MIPI (MIPIb), using the formula: MIPIb = MIPI + 0.02142 x Ki-67 (%). The additional Ki-67 term shifts the intermediate/high risk boundary from 6.20 (MIPI) to 6.50 (MIPIb), reflecting the added prognostic information. Studies have shown that Ki-67 greater than or equal to 30% is associated with a median overall survival of only about 2.2 years, whereas Ki-67 below 10% or 10-29% carries substantially better outcomes (median OS 7.2 and 6 years respectively). When pathology results include a Ki-67 proliferation index, using MIPIb is preferred because it more precisely identifies the highest-risk patients who may benefit most from intensive regimens or clinical trial enrollment.
Interpreting Your Results and Clinical Context
Low-risk patients (MIPI < 5.70) have a 5-year overall survival of approximately 60% and a median OS that was not reached during the original follow-up of ~32 months. Some truly indolent presentations may be eligible for watchful waiting, but this is a clinical judgment and most patients eventually require treatment. Intermediate-risk patients (MIPI 5.70-6.20) have a median OS of roughly 51 months and typically receive immunochemotherapy (most commonly rituximab-based induction) with consideration of autologous stem cell transplantation (ASCT) in younger, fit patients. High-risk patients (MIPI >= 6.20) have a median OS of approximately 29 months; for younger fit patients, intensive regimens followed by ASCT consolidation are often considered, while older or frailer patients may receive less intensive regimens. The MIPI is a prognostic tool, not a treatment algorithm. Treatment decisions must also account for patient age, comorbidities, performance status trajectory, patient preferences, and access to clinical trials.
MIPI Risk Groups and Median Survival
| Score Range | Risk Group | Median Overall Survival | Notes |
|---|---|---|---|
| <5.70 | Low | Not reached (~60% at 5 years) | Observation may be considered if asymptomatic |
| 5.70 to <6.20 | Intermediate | ~51 months | Immunochemotherapy +/- ASCT |
| >=6.20 | High | ~29 months | Immunochemotherapy +/- ASCT |
Based on the original derivation cohort (Hoster et al., Blood 2008). MIPIb thresholds differ from continuous MIPI for the intermediate/high boundary.
Frequently asked questions
What does MIPI stand for?
MIPI stands for Mantle Cell Lymphoma International Prognostic Index. It was developed by Eva Hoster and colleagues at the European Mantle Cell Lymphoma Network and published in Blood in 2008. The index combines four routinely measured clinical variables to predict overall survival in patients with advanced-stage mantle cell lymphoma.
What unit should I use for WBC?
Enter the WBC count in units of 10^9 cells per litre. This is the same as 10^3 cells per microlitre (mcL) or 10^3 cells per cubic millimetre (mm^3), which most laboratory reports use. A typical normal adult WBC count is roughly 4 to 11 x 10^9/L. Do not enter the raw cell count in cells per litre; that would produce an incorrect result.
What is the upper limit of normal (ULN) for LDH and where do I find it?
The ULN for LDH is specific to the laboratory assay and reagent method used. It is always printed on the laboratory report next to the patient result. Common values range from about 120 to 250 U/L depending on the institution and analyzer. Using the correct ULN from the same report as the patient LDH value is essential for an accurate score, because the formula uses the ratio LDH/ULN rather than the raw LDH level.
How is the simplified MIPI (sMIPI) different from the continuous MIPI?
The continuous MIPI uses the actual numeric values of all four variables in a logarithmic formula and produces a decimal score. The simplified MIPI (sMIPI) instead assigns 0 to 3 points per variable based on predefined cutpoints and sums the points to give a whole-number score from 0 to 11. Both versions define the same three risk groups, and subsequent studies have confirmed similar prognostic performance. The simplified version is quicker to compute mentally or on paper, while the continuous version is more precise for borderline cases.
Should I use MIPI or MIPIb?
Use MIPIb when a Ki-67 proliferation index from tumor immunohistochemistry is available, as it provides more refined risk stratification, especially for identifying very high-risk patients within the high-risk group. When Ki-67 is not available (for example, when relying on peripheral blood flow cytometry without tissue biopsy), the standard MIPI remains the validated approach. In practice, most pathology reports from lymph node or bone marrow biopsies in MCL include a Ki-67 result.
Does the MIPI apply to all stages of mantle cell lymphoma?
The MIPI was derived from and validated in cohorts of patients with advanced-stage (Ann Arbor stage III-IV) mantle cell lymphoma, which represents the vast majority of newly diagnosed MCL cases. Most patients present with advanced disease at diagnosis, so the MIPI is broadly applicable. The leukemic, non-nodal variant of MCL, which typically has a more indolent course and low or undetectable Ki-67, may not be fully captured by the MIPI risk groups. Clinical judgment incorporating the full clinical picture remains essential.
Is a higher or lower MIPI score better?
A lower MIPI score is better. A score below 5.70 indicates low risk with a 5-year overall survival of approximately 60%. The score rises with increasing age, worse performance status, higher LDH relative to the upper limit of normal, and higher white blood cell count. Scores of 6.20 or higher identify high-risk patients with a median overall survival of about 29 months in the original cohort.
Sources
- Hoster E, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008;111(2):558-565.
- Hoster E, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European MCL Network. J Clin Oncol. 2016;34(12):1386-1394.